| Year |
Citation |
Score |
| 2014 |
Kocsis P, Gyertyán I, Éles J, Laszy J, Hegedűs N, Gajári D, Deli L, Pozsgay Z, Dávid S, Tihanyi K. Vascular action as the primary mechanism of cognitive effects of cholinergic, CNS-acting drugs, a rat phMRI BOLD study. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 34: 995-1000. PMID 24643080 DOI: 10.1038/Jcbfm.2014.47 |
0.304 |
|
| 2011 |
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochemistry International. 59: 925-35. PMID 21767587 DOI: 10.1016/J.Neuint.2011.07.002 |
0.315 |
|
| 2010 |
Hellinger E, Bakk ML, Pócza P, Tihanyi K, Vastag M. Drug penetration model of vinblastine-treated Caco-2 cultures. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 41: 96-106. PMID 20595016 DOI: 10.1016/J.Ejps.2010.05.015 |
0.34 |
|
| 2010 |
Tihanyi K, Bakk ML, Hellinger E, Vastag M. CYP Inhibition-Mediated Drug-Drug Interactions Current Enzyme Inhibition. 6: 130-145. DOI: 10.2174/157340810793384106 |
0.3 |
|
| 2008 |
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B. Physico-chemical characterization of a novel group of dopamine D(3)/D(2) receptor ligands, potential atypical antipsychotic agents. Journal of Pharmaceutical and Biomedical Analysis. 48: 678-84. PMID 18692339 DOI: 10.1016/J.Jpba.2008.06.021 |
0.334 |
|
| 2007 |
Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse. The Journal of Pharmacology and Experimental Therapeutics. 320: 1268-78. PMID 17170312 DOI: 10.1124/Jpet.106.107920 |
0.321 |
|
| 2006 |
Borbás T, Benko B, Dalmadi B, Szabó I, Tihanyi K. Insulin in flavin-containing monooxygenase regulation. Flavin-containing monooxygenase and cytochrome P450 activities in experimental diabetes. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 28: 51-8. PMID 16488120 DOI: 10.1016/J.Ejps.2005.12.011 |
0.621 |
|
| 2004 |
Szöko E, Tábi T, Borbás T, Dalmadi B, Tihanyi K, Magyar K. Assessment of the N-oxidation of deprenyl, methamphetamine, and amphetamine enantiomers by chiral capillary electrophoresis: an in vitro metabolism study. Electrophoresis. 25: 2866-75. PMID 15352021 DOI: 10.1002/Elps.200406023 |
0.628 |
|
| 2003 |
Dalmadi B, Leibinger J, Szeberényi S, Borbás T, Farkas S, Szombathelyi Z, Tihanyi K. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 631-6. PMID 12695352 DOI: 10.1124/Dmd.31.5.631 |
0.634 |
|
| 1996 |
Keyvani-Amineh H, Diouri M, Tihanyi K, Weber JM. Adenovirus Type 2 Endoprotease: Isoforms and Redox Effects Journal of General Virology. 77: 2201-2207. PMID 8811020 DOI: 10.1099/0022-1317-77-9-2201 |
0.32 |
|
| 1994 |
Rancourt C, Tihanyi K, Bourbonniere M, Weber JM. Identification of active-site residues of the adenovirus endopeptidase Proceedings of the National Academy of Sciences of the United States of America. 91: 844-847. PMID 8302855 DOI: 10.1073/Pnas.91.3.844 |
0.312 |
|
| 1989 |
Tihanyi K, Fontanell A, Thirion JP. Gene regulation during anaerobiosis in soya roots Biochemical Genetics. 27: 719-730. PMID 2627197 DOI: 10.1007/Bf02396063 |
0.3 |
|
| Show low-probability matches. |